Search

Author/Creator Modesto, I

3. DOP61 Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study. (27th May 2021)

Authors:
Sandborn, W J; Dubinsky, M C; Torres, J; Vermeire, S; Kotze, P G; Su, C; Lawendy, N; Paulissen, J; Mundayat, R; Gardiner, S; Kulisek, N; Modesto, I; D'Haens, G R
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S096
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study. (15th January 2020)

Authors:
Sands, B E; Moss, A C; Armuzzi, A; Marshall, J K; Lindsay, J O; Sandborn, W J; Danese, S; Zeroncio, M; Modesto, I; Salese, L; Lawendy, N; Zhang, H; Su, C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 14(2020)Supplement 1
Page Start:
S110
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P336 Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study. (27th May 2021)

Authors:
Dubinsky, M C; D'Haens, G R; Sandborn, W J; Ng, S C; Panés, J; Su, C; Lawendy, N; Lazariciu, I; Gardiner, S; Mundayat, R; Kulisek, N; Modesto, I; Torres, J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S361
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. (30th January 2023)

Authors:
Peyrin-Biroulet, L; Dubinsky, M C; Sands, B E; Panés, J; Schreiber, S; Reinisch, W; Feagan, B G; Danese, S; Yarur, A; D'Haens, G; Goetsch, M; Wosik, K; Wu, J; Modesto, I; McDonnell, A; Bartolome, L; Rabbat, C J; Vermeire, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i536
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study. (27th May 2021)

Authors:
D'Haens, G R; Dubinsky, M C; Regueiro, M; Santana, G O; Torres, J; Kulisek, N; Gardiner, S; Mundayat, R; Paulissen, J; Lawendy, N; Su, C; Modesto, I; Sandborn, W J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S416
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme. (30th January 2023)

Authors:
Vermeire, S; Yarur, A; Rubin, D T; Dubinsky, M C; Regueiro, M; Irving, P; Peyrin-Biroulet, L; Goetsch, M; Gu, G; Wu, J; Modesto, I; McDonnell, A; Rabbat, C J; Green, J; Anthopoulos, P
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i604
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P558 Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials. (30th January 2023)

Authors:
Regueiro, M; Siegmund, B; Yarur, A; Steinwurz, F; Gecse, K B; Goetsch, M; Bhattacharjee, A; Wu, J; Green, J; McDonnell, A; Crosby, C; Lazin, K; Ferreira Branquinho, D; Modesto, I; Abreu, M T
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i689
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P602 Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. (30th January 2023)

Authors:
Magro, F; Peyrin-Biroulet, L; Sands, B E; Danese, S; Jairath, V; Goetsch, M; Bhattacharjee, A; Wu, J; Ferreira Branquinho, D; Modesto, I; Feagan, B G
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i728
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗